Skip to Main content Skip to Navigation
Journal articles

Abemaciclib, a Recent Novel FDA-Approved Small Molecule Inhibiting Cyclin-Dependant Kinase 4/6 for the Treatment of Metastatic Breast Cancer: A Mini-Review

Abstract : Abemaciclib (Verzerio®) is a cell cycle inhibitor of both CDK4 and CDK6. In 2017, abemaciclib was approved by the Food and Drug Administration (FDA) and, in 2018 by the European Medicines Agency (EMA) for the treatment of postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) advanced breast cancer. In this mini-review, we provide a series of information for respectively their targets and its selectivity, results on preclinical trial, clinical phase I, II and III trials, and some perspectives. We also describe the batch and flow steps used for the synthesis of this cancer drug.
Complete list of metadata

https://hal-univ-rennes1.archives-ouvertes.fr/hal-03137824
Contributor : Laurent Jonchère <>
Submitted on : Wednesday, February 10, 2021 - 4:40:18 PM
Last modification on : Wednesday, April 7, 2021 - 3:18:14 PM
Long-term archiving on: : Tuesday, May 11, 2021 - 8:47:02 PM

File

Voli et al-2020-Abemaciclib, a...
Files produced by the author(s)

Identifiers

Citation

Lou Anna Voli, Janat A. Mamyrbékova, Jean-Pierre Bazureau. Abemaciclib, a Recent Novel FDA-Approved Small Molecule Inhibiting Cyclin-Dependant Kinase 4/6 for the Treatment of Metastatic Breast Cancer: A Mini-Review. Open Journal of Medicinal Chemistry, 2020, 10 (03), pp.128-138. ⟨10.4236/ojmc.2020.103007⟩. ⟨hal-03137824⟩

Share

Metrics

Record views

81

Files downloads

103